Collection of Safety, Efficacy and Resource Utilization Information in Patients Who Have Received Melphalan PHP with the Delcath Hepatic Delivery System for the Treatment of Unresectable Hepatic Malignancy
Post Marketing study: The CHEMOSAT kit containing Gen 2 filters has been used to treat patients since April 2012. This registry study is designed to collect safety, resource utilization and treatment outcomes in patients who receive this treatment with CHEMOSAT by healthcare professionals. The safety and efficacy data from patients treated with CHEMOSAT is important in updating the safety profile and for collection of treatment information. The resource utilization information is essential in planning treatment strategy for patients. This registry does not follow any pre-determined protocol with respect to diagnosis, treatment or follow-up of the patient. The data collected will be gathered exclusively from current medical practice at participating institutions. Delcath holds a list of authorized customer hospitals to whom it supplies the CHEMOSAT System. To date these hospitals have treated over 300 patients with cancers of the liver. The decision to treat with CHEMOSAT is clearly separated from the decision to collect data in the registry. No specific procedures or tests are required in this protocol.
Study Type
OBSERVATIONAL
Enrollment
200
Southampton University Hospitals and University of Southampton
Southampton, United Kingdom
RECRUITINGSpire Southampton Hospital
Southampton, United Kingdom
RECRUITINGGather key safety data on the use of CHEMOSAT Kit (Gen 2 filter).
Data to be collected at: Baseline, treatment and post treatment laboratory values and clinical measurements until time of discharge
Time frame: Post-procedure (up to 30 days after CS-PHP)
Percentage of treatment with CHEMOSAT each patient receives
The percentage of treatments with CHEMOSAT each patient receives based on primary tumor
Time frame: From the first CHEMOSAT treatment through the last, [timeframe an average of 12-months if 6 cycles completed]
Evaluation of Best Overall Response
Evaluation of patient best overall response (partial response or complete response, when applicable)
Time frame: from the date of first CHEMOSAT treatment through last CHEMOSAT treatment, or treatment discontinuation or death (whichever occurs first) [assessed up to 24 months]
Evaluation of resource utilization
Percentage of days spent in ICU, step-down area
Time frame: From the first CHEMOSAT treatment through the last CHEMOSAT treatment [assessed up to 24 months]
Evaluate time to treatment failure
Time of first CHEMOSAT treatment to time of treatment failure
Time frame: time from first CHEMOSAT treatment to the date of last CHEMOSAT treatment [assesed up to 24 months]
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.